# Efficacy and Safety of Rilpivirine-Based Antiretroviral Therapy in Treatment-Naïve and Treatment-Experienced HIV-1-Positive Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

**Lazzarin A¹, Rusconi S², Antinori A³, Galeone C⁴, Uglietti A⁵, Termini R⁵ and Mancusi D⁵***

¹Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy  
²Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy; Unità Operativa Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese  
³HIV/AIDS Department, National Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, Roma, Italy  
⁴Biostatistics & Outcome Research Unit, Statinfo, Renate, Italy  
⁵Medical Affairs Department, Infectious Diseases, Janssen-Cilag SpA, Cologno Monzese, Italy

*Corresponding author: Dr. Daniela Mancusi, MSc, Biotechnologist, Medical Affairs Department, Infectious Diseases, Janssen-Cilag SpA, Via Michelangelo Buonarroti, 23, 20093 Cologno Monzese, Milano, Italy, Tel: +39-345-9581-944

## Abstract

Rilpivirine (RPV) is a second-generation non-nucleoside reverse-transcriptase inhibitor used in combination antiretroviral therapy (cART) in naive and experienced HIV-positive adult subjects. To evaluate its efficacy and safety in these patient settings, we performed a meta-analysis of randomized controlled trials with available data at 48 and 96 weeks of follow-up. We considered 4 studies involving 2336 cART-naïve patients and 8 studies involving 3165 cART-experienced virologically controlled patients. Regarding efficacy, the virological response rate and the mean difference in the change from the baseline CD4 cell count were not significantly different between the RPV and comparator arms in both patient groups at both time points. Regarding safety, the discontinuation rates due to any adverse events (AEs), serious AEs, RPV-related AEs and AEs leading to drug discontinuation did not significantly differ from the rates in the comparator group at both time points. A systematic review of lipid changes was also performed: the safety and advantageous metabolic impact of RPV on lipids, especially among cART-naïve subjects at up to 96 weeks of follow-up, were confirmed. Our meta-analysis indicated that RPV-based regimens were effective and tolerable for both types of patients, which was consistent with published data from real-life settings.

## Introduction

Rilpivirine (RPV; TMC278; Edurant®) is a second-generation non-nucleoside reverse-transcriptase inhibitor (NNRTI) with activity against many viral strains resistant to previous NNRTIs and a moderate-high genetic barrier to resistance development [1,2]. RPV efficacy and safety have been assessed in registrative randomized controlled clinical trials (RCTs) in HIV-positive treatment-naïve [3-7] and treatment-experienced patients [8-14] with documented long-term efficacy and tolerability. Real-life data from observational studies [15-21] eventually confirmed these results. Therefore, current Italian [22], European [23], British [24,25] and DHHS (Department of Health and Human Services) [26] HIV/AIDS guidelines recommend the use of RPV as a first-line third agent coupled with a nucleoside reverse transcriptase inhibitor backbone in people living with HIV (PLWH) with CD4 count > 200 cells/μL and HIV RNA < 100,000 copies/mL starting combination antiretroviral therapy (cART) and in optimization strategies represented by RPV-based single tablet regimens (both standard three-
mediated hepatic oxidation, no inhibition or induction of cytochrome P-450 isoenzymes has been reported, and its spectrum of interaction is favorably narrowed [1,2,27].

To date, one meta-analysis in 2014 has been performed on the efficacy and safety of RPV in treatment-naïve only adult PLWH, with efavirenz (EFV) [30] as the comparator. Considering the changing clinical background, as well as the versatility and various advantages of RPV, we conducted a systematic review and meta-analysis to evaluate the 48-week and long-term (defined as at least 96 weeks) efficacy (as the proportion of plasma HIV RNA < 50 cp/mL and as the change in CD4 cell count) and safety (as the incidence of adverse events and as the change in lipid levels) of RPV-based cART compared to other current cART regimens in both treatment-naïve and treatment-experienced virologically suppressed PLWH. The data reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [31].

RPV is administered orally as a 25-mg tablet once daily with food and is available alone or as a fixed-dose combination with emtricitabine/tenofovir (disoproxil or alafenamide) or with dolutegravir. No dosage adjustment is recommended for patients with renal dysfunction or mild-to-moderate hepatic insufficiency [1,2,27]. Although RPV is metabolized by CYP3A4-mediated hepatic oxidation, no inhibition or induction of cytochrome P-450 isoenzymes has been reported, and its spectrum of interaction is favorably narrowed [1,2,27].

Figure 1: Flowchart describing the literature search and study selection process.

*Including two articles from which we extracted information on changes in lipid levels separately from the ECHO and THRIVE trials at 48 weeks of follow-up and 2 articles from the TMC278-C204 and SWORD 1&2 trials reporting results at 192 and 148 weeks of follow-up, respectively, that were not used in the meta-analyses.

Abbreviations: RCT: Randomized clinical trial; RPV: Rilpivirine.
Methods

Search strategy

Relevant studies were identified by systematic electronic literature searches in the Medline/PubMed, EMBASE and Cochrane Library databases from inception to June 2019. No language restriction was applied. The detailed search strategy is described in the Supplementary Methods. In addition, we manually reviewed the references of recent reviews and meta-analyses and of all the papers selected for inclusion to identify additional studies that met the inclusion criteria. The flowchart with detailed information on the search and selection process is presented in Figure 1.

Inclusion and exclusion criteria

RCTs with at least 48 weeks of follow-up and comparing the efficacy (viral suppression) and safety of RPV use (dose: 25 mg/day) with other cART in adult PLWH were included. Observational studies, reviews, meta-analyses, commentaries without original data, phase 1 studies, pharmacokinetic or bioequivalence studies on healthy subjects, pre-exposure prophylaxis studies, cost-effectiveness analyses, and non-English-language articles were excluded. The conference abstracts of relevant RCTs were considered only if a full-length publication was not available. Single-arm studies, studies based on special populations (i.e., pregnant women), studies investigating long-acting RPV, studies in which RPV was used in both arms and for the same time period, and studies with a follow-up shorter than 48 weeks were also excluded. Studies comparing immediate to delayed switch to RPV-based regimens were considered eligible, and the delayed switch arm was used as the comparator in the analyses. In the case of multiple publications from the same trial, we selected the main trial publications with results of the primary efficacy outcome (i.e., viral suppression) at 48 and 96 (±8) weeks of follow-up. No studies were excluded a priori for weakness of design or data quality.

Study selection, data extraction and risk of bias assessment

The merging of the records identified from Medline/PubMed, EMBASE and the Cochrane Library resulted a total of 1064 unique records. Two reviewers independently screened the titles and abstracts of all the retrieved articles and examined the full texts of the articles considered potentially eligible for inclusion (n = 58). Any disagreements were resolved by consensus. Eighteen articles met the inclusion criteria and were included in the systematic review [3-14,28,32-36] (Table 1). Four of these articles were presented in tables and were not included in the quantitative meta-analyses of the efficacy and safety outcomes. They were the two separate publications of the ECHO [3] and THRIVE [4] trials at 48 weeks of follow-up (which were used when reporting results for lipid values, as the publication of the pooled analysis did not detail such quantitative information [36]) and the publications at 148 weeks of follow-up of the SWORD 1-2 trials [35] and at 192 weeks of the TMC278-C204 trial [6] (which were not used in the meta-analyses, as no other study had data for a comparable follow-up period). Thus, a total of 14 publications [5,7-14,28,32-34,36], which provided results on 12 distinct RCTs at 48 and/or 96 (±8) weeks of follow-up, were included in the meta-analyses. The data were extracted from the selected articles in a standardized format by 2 independent reviewers. The data collected from each study included trial name, enrollment period, geographic area, number of patients included and treatment regimens, patient characteristics at baseline (e.g., cART-naive or experienced patients), cut-off for plasma viral load and CD4 cell count for inclusion, age, and treatment duration before study inclusion for cART-experienced patients), duration of follow-up, and results for the efficacy and safety endpoints according to the ITT analysis. Data on viral suppression according to plasma viral load and CD4 cell count at baseline were also extracted from trials on cART-naive patients. When available, the results of the US Food and Drug Administration (FDA) Snapshot algorithm were extracted. Our primary efficacy endpoint was the proportion of participants with viral suppression (defined as HIV RNA levels < 50 copies/mL) at 48 and 96 (±8) weeks of follow-up. One study that defined viral suppression as HIV RNA levels < 40 copies/mL was also considered [14]. The secondary efficacy endpoint was the change in CD4 cell counts from baseline at 48 and 96 (±8) weeks of follow-up. Safety endpoints include the number of any AEs, serious AEs, drug-related AEs and AEs leading to study discontinuation. Information on the change in lipids and glucose levels at 48 and 96 weeks of follow-up was also extracted. The TMC278-C204 study was a dose-ranging trial with three once-daily RPV doses (i.e., 25, 75 or 150 mg) [33]. In the meta-analyses, we included the results for the 25 mg dose only. The LATTE trial design included a 24-week induction phase assessing the antiviral activity and safety of 3 different cabotegravir doses over efavirenz in cART-naive adult PLWH, followed by a 72-week maintenance phase assessing cabotegravir plus RPV (over EFV) for the maintenance of viral suppression [28]. Only results based on the maintenance-exposed population were included in the meta-analyses. That patient population was considered ART-experienced. The individual study quality assessment was performed with Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) [37] in relation to the specific outcome plasma HIV RNA.

Statistical analysis

The meta-analyses of the efficacy outcomes (i.e., HIV RNA levels < 50 copies/mL and change in CD4 cell counts from baseline) were conducted separately for the 48-week and 96-week time points and for the treatment-
Table 1: Main characteristics of trials comparing rilpivirine (RPV)-based regimens with other antiretroviral therapies (ART).

| Type of Clinical Trial | Study Period | Geographic Area | Control Group Regimen | Control Group (naïve/virologically suppressed) of Enrolled Patients | Treatment-naïve patients | RPV Regimen Group | RPV Regimen (naïve/virologically suppressed) of Enrolled Patients |
|------------------------|--------------|-----------------|-----------------------|--------------------------------------------------|--------------------------|-------------------|--------------------------------------------------|
| Trial | Reference(s) | | | Patient Characteristics at Baseline: | | | |
| | | | | - age (mean/median) | - cut-off for plasma viral load (copies/ml) | - cut-off for CD4 cell count (μL) | - time since treatment started (for treatment-experienced patients) | |
| | | | | | | | - pVL > 5000 | - CD4 not limited |
| | | | | | | | 4-week screening period | 4-week follow-up |
| | | | | | | | 96-week treatment | 4-week follow-up |
| | | | | | | | 96-week treatment | 6-week screening period | 4-week follow-up |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| Treatment-naive | Treatment-experienced, virologically controlled patients |
|----------------|----------------------------------------------------------|
| THRIVE         | SPirit                                                   |
| NCT0053725     | GS-US-264-0106                                          |
| Cohen 2011 [4] | Palella 2014 [10]                                       |
| Phase 3        | Phase 3b                                                 |
| randomized     | randomized                                               |
| double-blind   | open-label                                               |
| noninferiority | noninferiority                                           |
| multicenter    | multicenter                                              |
| trial          | trial                                                    |
| Pooled analysis with THRIVE; Cohen 2012 [8] | Van Lunzen 2016 [7]                                     |
| (week 48 results) | (week 48 results)                                       |
| (week 48 results) | (week 96 results)                                       |
| 21 countries (USA, Puerto Rico, Canada, Australia, South Africa, 4 in Europe, 4 in Asia, and 6 in Latin America) | Europe and USA, 9 countries |
| 340:338        | 317:152                                                  |
| Treatment-naive | Treatment-naive                                         |
| 340:338        | 340:338                                                  |
| 2008-2011      | 2010-2012                                                |
| Phase 3b       | Phase 3b                                                 |
| randomized     | randomized                                               |
| double-blind   | open-label                                               |
| noninferiority | noninferiority                                           |
| multicenter    | multicenter                                              |
| trial          | trial                                                    |
| STAR           | STAR                                                     |
| NCT01309243    | NCT01252940                                             |
| Cohen 2012 [5] | Palella 2014 [10]                                       |
| (week 48 results) | (week 96 results)                                       |
| 12 countries (USA, Canada, Puerto Rico and 8 countries in Europe) | Europe and USA, 9 countries |
| 394:392        | 317:152                                                  |
| Treatment-naive | Treatment-naive                                         |
| 394:392        | 340:338                                                  |
| 2011-2013      | 2010-2012                                                |
| Phase 3b       | Phase 3b                                                 |
| randomized     | randomized                                               |
| open-label     | open-label                                               |
| noninferiority | noninferiority                                           |
| multicenter    | multicenter                                              |
| trial          | trial                                                    |

Pooled analysis with THRIVE; Cohen 2012 [8]

Day 1-week 24: ongoing PI + RTV
Week 24-48: RPV (25 mg/day) + FTC/TDF

Treatment-naive

- 36 y (median age) in the RPV group and 36 in the control group
- pVL ≥ 5000
- CD4 not limited

6-week screening period
96-week treatment
4-week follow-up

 barbar

Phase 3 randomized double-blind noninferiority multicenter trial

TDF/FTC/ABC/3TC

96-week treatment

RPV (25 mg/day) + TDF

Cohen 2011 [4]

48 results

Pooled analysis with THRIVE; Cohen 2012 [8]

(week 48 results)

Cohen 2012 [36]

Cohen 2013 [5]

(week 96 results)

Pooled analysis with THRIVE; Cohen 2012 [8]

(week 48 results)

Cohen 2012 [36]

Cohen 2013 [5]

(week 96 results)

Pooled analysis with THRIVE; Cohen 2012 [8]

(week 48 results)

Cohen 2012 [36]

Cohen 2013 [5]

(week 96 results)
| Study | Design | Duration | Country | Virological Suppression Criteria | Switch | Continuation |
|-------|--------|----------|---------|---------------------------------|--------|--------------|
| LATTE | Phase 2b randomized open-label multicenter trial | 2012-2018 | USA and Canada | pVL ≥ 1000 (at start of induction phase), vireologically suppressed by week 24, pVL ≥ 400 by week 72 | | |
|        | Maintenance phase: CAB (10 mg/30 mg/60 mg/day) + one of the following regimens: TDF/FTC - ABC/3TC | | | | | |
|        | Maintenance phase: RPV (25 mg/day) + CAB (10 mg/30 mg/60 mg/day) + one of the following regimens: TDF/FTC - ABC/3TC | | | | | |
|        | Probe | 2014 | Italy | vireologically suppressed (on PI + RTV + 2NRTIs for ≥ 6 months) | | |
|        | Margiolo 2016 [11] | | | | | |
| Probe | Proof-of-concept noninferiority single-center trial | 438:437 | USA, Canada, and 6 countries in Europe | | | |
| GS-US-366-1160 | Phase 3b randomized double-blind noninferiority multicenter trial | 2015-2019 | | vireologically suppressed (on EFV/FTC/TDF for ≥ 6 months) | | |
|        | NCT02345226 DeJesus 2017 [34] (week 48 results), Hagins 2018 [12] (week 96 results) | | | | | |
| GS-US-366-1160 | Phase 4 randomized open-label noninferiority single-center trial | 2014 | Italy | | | |
| Probe | Magiolo 2016 [11] | | | | | |
| Probe | | | | | | |


| Study | Trial Description | Phase | Randomized | Open-label | Noninferiority | Multicenter | Start Date | Countries | Participants | Virologically Suppressed | Median Age (y) | Median ART Duration (y) | pVL < 50 | CD4 | Treatment Schedule |
|-------|-------------------|-------|------------|------------|---------------|-------------|------------|------------|-------------|---------------------|----------------|------------------------|---------|-----|-------------------|
| SWORD-1 | NCCT04242791 Libreville 2018 [9] (week 48 results) | Phase 3 | Randomized | Open-label | Noninferiority | Multicenter | 2018-2019 | 12 countries (USA, Canada, Argentina, Taiwan, Russian Federation and 7 countries in Europe) | 1,074 | For at least 6 months before enrollment | 43.6 | 51 months | RPV (25 mg/day) + TDF + FTC |
| SWORD-2 | NCCT04242797 Libreville 2018 [9] (week 100 results) | Phase 3 | Randomized | Open-label | Noninferiority | Multicenter | 2018-2019 | 12 countries (USA, Canada, Argentina, Taiwan, Russian Federation and 7 countries in Europe) | 1,074 | For at least 6 months before enrollment | 43.6 | 51 months | RPV (25 mg/day) + TDF + FTC |
| SALIF | Muratori 2019 [13] | Phase 3b | Randomized | Open-label | Noninferiority | Multicenter | 2013-2015 | 12 countries (1 country in Europe) | 213 | Virologically suppressed | 40.6 | 5.2 | RPV (25 mg/day) + FTC |
| SALIF | Muratori 2019 [13] | Phase 3b | Randomized | Open-label | Noninferiority | Multicenter | 2013-2015 | 12 countries (1 country in Europe) | 213 | Virologically suppressed | 40.6 | 5.2 | RPV (25 mg/day) + FTC |
| Petchkum | Muratori 2019 [14] | Randomized | Noninferiority | Single-center | Trial | 2016-2017 | Thailand | 51 | Virologically suppressed (on NVP-based ART for ≥ 6 months) | 48 | 10 | Both | RPV (25 mg/day) + one of the following regimens: TDF/3TC, TDF/FTC |

**Abbreviations:** ART: Antiretroviral therapy; RPV: Rilpivirine; EFV: Efavirenz; TDF: Tenofovir disoproxil fumarate; FTC: Emtricitabine; AZT: Zidovudine; NVP: Nevirapine; DRV: Darunavir; RTV: Ritonavir; ATV: Atazanavir; PI: Protease inhibitor; TAF: Tenofovir alafenamide; DTG: Dolutegravir; CAB: Cabotegravir.

§ The pooled analysis of the ECHO and THRIVE trials included 686 patients in the RPV arm (RPV 25 mg/day plus one of the following regimens: TDF/FTC, A2Z/TC or ABC/3TC). Double-blinded to RPV doses; open-label to placebo. We considered the arm with an RPV dose of 25 mg/day in the meta-analysis.

*Double-blinded to cabotegravir doses; open-label to the assignment of cabotegravir (and RPV in the maintenance phase) or EFV.

"60, 60, and 61 patients treated with 10 mg, 30 mg and 60 mg of cabotegravir, respectively.
naive and treatment-experienced virologically controlled patients. In the meta-analyses of the safety outcomes, we combined all the trials and used the data at the longest follow-up. Risk ratios comparing the number of events in patients treated with RPV-based ART versus those treated with other ART were used as the effect measures for the viral suppression and AE endpoints. For the CD4 cell count endpoint (change from baseline), we used the weighted mean difference as the effect measure. Study-specific RRs (and 95% CIs) of viral suppression and AEs were calculated from the distribution of the outcomes in the RPV and comparator arms. Study-specific mean differences and 95% CIs in the change in CD4 cell count from baseline for the RPV arm vs. the comparator arm were calculated from the mean values of the change and the corresponding standard deviations, standard errors or 95% CIs in the two arms. The summary RR and mean difference were estimated through random-effects models to take into account the heterogeneity of the risk estimates, using the moment estimator of the variance across studies as the weight [38,39]. Heterogeneity among trials was evaluated using the χ² test (defined as a p-value less than 0.10), and inconsistency was measured using the I² statistic, i.e., the percentage of total variation attributable to among-study heterogeneity rather than chance (values of the I² statistic of approximately 25%, 50% and 75% are indicative of low, moderate and high heterogeneity, respectively) [40]. Publication bias was evaluated through the examination of funnel plots and tests proposed by Begg and Mazumdar and Egger [41,42]. We conducted sensitivity analyses by excluding each study one by one from the meta-analysis and subgroup analyses of viral suppression according to viral load (< 100,000 copies/mL and ≥ 100,000 copies/mL) and CD4 cell count (< 200 cells/mm³) at baseline in treatment-naive patients. All statistical analyses were performed using STATA software (version 14.1; StataCorp, College Station, TX, USA).

Results

A search of electronic scientific databases led to a total of 1064 records. After title and abstract reviewing and checking for duplicates using Endnote X7 software, we excluded 1006 records mainly because they presented data from populations or study designs not matching our inclusion criteria (i.e., healthy subjects, observational studies) or not reporting original data (i.e., reviews, commentaries, opinion letters). Fifty-eight articles on RPV were thoroughly analyzed: All the full texts were downloaded and evaluated for the inclusion in this meta-analysis. Another 40 of these articles were excluded mainly because they reported replicated data or matched one or more of our exclusion criteria. At the end of the study selection process, after excluding the last 4 articles exclusively used for extracting data on RPV safety for the qualitative synthesis of lipid changes, 14 original articles reporting on 12 distinct RCTs were eventually included and presented in the meta-analysis. A brief flow-chart of the study selection process is shown in Figure 1. Two study groups were considered based on the treatment status of the enrolled patients: cART-naïve and cART-experienced virologically suppressed subjects. Only studies with available 48 and 96 weeks data of follow-up were included to perform the meta-analysis. The characteristics of both studies design and enrolled patients included in our analysis are reported in Table 1. The main results in terms of changes in CD4 cell counts, lipids and glucose levels of the studies included in the meta-analysis are summarized in Supplementary Table 1 and Supplementary Table 2.

Individual study quality assessment is depicted in Supplementary Figure 1. The study protocols were obtained where available to assess selective outcome reporting. All the studies detailed the statistical process for the outcomes and addressed missing or incomplete data (i.e. loss to follow-up); therefore, the risks of bias due to either missing outcomes, measurement of the outcome or selection of the reported results were ranked as low. They all achieved adequate sequence generation and allocation concealment, but the use of blocked randomization of size 4 in a single recruitment center may suggest minor issues with the allocation concealment in the study by Petchkum, et al. [14]. Biases related to potential deviations from the intended interventions were also deemed low for all the RCTs, except for the PROBE study [11], which did not report detailed information on patient disposition to make a judgment.

Efficacy: Viral suppression

Efficacy was primarily defined as the proportion of participants with viral suppression (defined as plasma HIVRNA levels < 50 copies/mL) at 48 and 96 weeks (+ 8 weeks) for cART-naïve adult PLWH and at 48 weeks (+ 8 weeks) for cART-experienced virologically controlled adult PLWH.

For cART-naïve patients, we included 4 studies in this meta-analysis (TMC278-C204, ECHO, THRIVE and STAR) covering a total of 2336 adult patients evaluated at 48 and 96 weeks of follow-up from 5 distinct publications. In the intention-to-treat (ITT) analysis, the virological response rate with RPV was not significantly different from the comparator at weeks 48 and 96, with risk ratio (RR) values equal to 1.04 (95% confidence interval (CI) 1.00-1.08) and 1.03 (95% CI 0.98-1.09), respectively. A very low degree of heterogeneity was found between the RR estimates at week 48 (I² 0.0%, p = 0.706) and week 96 (I² 19.2%, p = 0.290; Figure 2).

For cART-experienced virologically controlled patients, data were available from 8 studies (SPIRIT, LATTE, PROBE, GS-US-366-1160, SWOrD-1, SWOrD-2, SALIF and NCT03664440) from 7 publications for a
baseline HIV RNA > 100,000 copies/mL either at week 48 (RR 0.96; 95% CI 0.90-1.03) or at week 96 (RR 0.96; 95% CI 0.88-1.05; data not shown). In contrast, among patients starting an RPV-based regimen with baseline HIV RNA < 100,000 copies/mL, the RPV group weakly trended toward a better virological response rate than the comparator at weeks 48 (RR 1.08; 95% CI 1.03-1.13) and 96 (RR 1.07; 95% CI 1.01-1.13; data not shown). At both follow-up times, the virological response rate in the RPV group was not significantly different from that in the comparator among patients starting cART with either a CD4 count above or below 200 cells/μL, except at week 48. In the latter case, patients with a CD4 count > 200 cells/μL showed a mild trend for a better virological response if starting RPV instead of the comparator (RR 1.06; 95% CI 1.02-1.11; data not shown).

In subgroup analyses conducted in naïve subjects at weeks 48 and 96, we calculated pooled RRs according to the baseline plasma viral load (2 studies, 2154 subjects) and the baseline CD4 cell count (2 studies, 2154 subjects). The virological response rate with RPV was not significantly different from the comparator among patients starting an RPV-based regimen with baseline HIV RNA > 100,000 copies/mL either at week 48 (RR 0.96; 95% CI 0.90-1.03) or at week 96 (RR 0.96; 95% CI 0.88-1.05; data not shown). In contrast, among patients starting an RPV-based regimen with baseline HIV RNA < 100,000 copies/mL, the RPV group weakly trended toward a better virological response rate than the comparator at weeks 48 (RR 1.08; 95% CI 1.03-1.13) and 96 (RR 1.07; 95% CI 1.01-1.13; data not shown). At both follow-up times, the virological response rate in the RPV group was not significantly different from that in the comparator among patients starting cART with either a CD4 count above or below 200 cells/μL, except at week 48. In the latter case, patients with a CD4 count > 200 cells/μL showed a mild trend for a better virological response if starting RPV instead of the comparator (RR 1.06; 95% CI 1.02-1.11; data not shown).

In subgroup analyses conducted in naïve subjects at weeks 48 and 96, we calculated pooled RRs according to the baseline plasma viral load (2 studies, 2154 subjects) and the baseline CD4 cell count (2 studies, 2154 subjects). The virological response rate with RPV was not significantly different from the comparator among patients starting an RPV-based regimen with

Figure 2: Meta-analysis of viral suppression (defined as HIV RNA levels < 50 copies/mL) for ART-naïve adult subjects at 48 (Panel A) and 96 (Panel B) weeks of follow-up.
Safety: Adverse events

Safety was primarily evaluated as the number of any adverse events (AEs), serious AEs, drug-related AEs and AEs leading to study discontinuation, using data at the longest follow-up and pooling together cART-naïve and cART-experienced patients; data were available from 8 (4549 subjects), 10 (4791 subjects), 9 (4515 subjects) and 12 studies (5467 subjects), respectively. As shown in Figure 6, Figure 7 and Figure 8 and Supplementary Figure 3, the RPV safety profile was not significantly different from that of the comparator according to any of the four assessed parameters. The pooled 48/96-week follow-up RRs for any AEs, serious AEs, drug-related AEs and AEs leading to study discontinuation were 1.01 (95% CI 0.97-1.05; Supplementary Figure 3), 1.04 (95% CI 0.78-1.39; Figure 6), 1.00 (95% CI 0.97, 1.03; 41.64) and 0.78 (95% CI 0.43-1.43; Figure 8), respectively. A moderate-high degree of heterogeneity was found among the studies’ RRs, except for the meta-analysis of any serious AEs (I2 48.7%, p = 0.069): any AEs (I2 66.8%, p = 0.010), drug-related AEs (I2 90.1%, p < 0.001) and AEs leading to discontinuation (I2 75.2%, p < 0.001; Figure 6, Figure 7 and Figure 8 and Supplementary Figure 3). No evidence of publication bias was detected (Supplementary Figure 2, panel B).

Efficacy: Changes in the baseline CD4 cell count

Efficacy was secondarily assessed in terms of the change in CD4 cell counts from baseline at 48 and 96 weeks (± 8 weeks) of follow-up for the cART-naïve adult group and at 48 weeks for the cART-experienced virologically controlled adult group.

For cART-naïve patients, data were available from 4 studies, for a total of 2336 adult PLWH evaluated at week 48 and week 96 (5 distinct publications; Supplementary Table 1). The ITT analysis showed that the mean difference (MD) in the change in CD4 cell counts from baseline to week 48 did not differ between RPV and the comparator group (MD 10.93; 95% CI -1.03-22.90; Figure 4), and a similar result was observed at week 96 (MD 8.01; 95% CI 6.94-22.95; Figure 4). The heterogeneity assessment showed no significant variability among the studies at either time point (Figure 4).

For cART-experienced virologically controlled patients, the mean and standard deviation at week 48 were available from 3 studies (1359 adult PLWH evaluated; Supplementary Table 1). Even in this group, the MD in the change in CD4 cell counts from baseline to week 48 did not differ between RPV and the comparator group (MD 14.01; 95% CI -1.62-29.64; Figure 5), and significant heterogeneity among the studies was not observed (Figure 5).

Safety: Changes in lipid levels

Available data from the included studies were not sufficient to perform a meta-analysis on the changes in lipid levels from baseline; therefore, we performed...
Panel A

**Summary mean difference in the change from baseline in CD4 cell count - week 48 - naive subjects**

| First author | Trial name  | Mean difference (95% CI) | Weight (%) |
|--------------|-------------|--------------------------|------------|
| Poznaiak 2010 | TMC278-C204 | -4.00 (-36.15, 27.35)    | 14.19      |
| Cohen 2012   | ECHO-THRIVE | 16.00 (-0.28, 32.28)     | 53.99      |
| Cohen 2014   | STAAR       | 9.00 (-12.21, 30.21)     | 31.82      |
| Overall (I-squared = 0.0%, p = 0.534) | | 10.93 (-1.03, 22.90) | 100.00     |

Panel B

**Summary mean difference of change from baseline in CD4 cell count - week 96 - naive subjects**

| First author | Trial name  | Mean difference (95% CI) | Weight (%) |
|--------------|-------------|--------------------------|------------|
| Poznaiak 2010 | TMC278-C204 | -14.00 (-49.39, 21.39)   | 17.11      |
| Cohen 2013   | ECHO-THRIVE | 9.00 (-10.10, 28.10)     | 53.45      |
| van Luzon 2016 | STAAR | 19.00 (-7.57, 45.57)     | 29.44      |
| Overall (I-squared = 7.1%, p = 0.341) | | 8.01 (-6.94, 22.95) | 100.00     |

**Figure 4:** Meta-analysis of the change in CD4 cell counts from baseline for ART-naïve adult subjects at 48 (Panel A) and 96 (Panel B) weeks of follow-up.

A systematic review on the changes in lipid levels from baseline at 48 weeks and at the longest follow-up (96 ± 4 weeks) for the cART-naïve and cART-experienced virologically controlled adult groups (Supplementary Table 2). For the former group, 3 (2154 subjects) [3,4,32] and 4 studies (1658 subjects) [5,7,33] were included for weeks 48 and 96, respectively. At week 48, total and LDL cholesterol showed no substantial variation in the RPV arms (from +1.0 to +3.09 and from -1.54 to +1.0 mg/dL, respectively), while there was a mild-to-moderate increase among the comparators (from +22.0 to +30.5 mg/dL, respectively). HDL cholesterol increased in both arms but more significantly in the comparator arms (from +2.0 to +4.25 mg/dL in RPV and from +8.0 to +10.4 mg/dL among the comparators). Triglycerides showed a mild reduction in patients treated with RPV (from -6.2 to -8.86 mg/dL) and an increase in patients treated with the comparator drugs (from +8.0 to +14.2 mg/dL). For all the studies, the changes in all these lipids from baseline differed between the arms at a statistically significant level (Supplementary Table 2).

At week 96, LDL changes spanned from +1.16 to +5.0 mg/dL in the RPV arms and from -5.0 to +29.0 mg/dL in
the comparator arms; HDL changes varied from +2.0 to +6.0 mg/dL in the RPV arms and from +9.0 to +11.2 mg/dL in the comparator arms; and total cholesterol changes ranged from +3.0 to +10.0 mg/dL in the RPV arms and from +25.0 to +34.0 mg/dL in the comparator arms. For triglycerides, 3 studies [5,33] observed a reduction among patients in the RPV arms (from -6.20 to -8.0 mg/dL) and a mild-to-moderate increase among patients

**Figure 5:** Meta-analysis of the change in CD4 cell count from baseline for ART-experienced virologically controlled adult subjects at 48 weeks of follow-up.

**Figure 6:** Meta-analysis of studies reporting data on any serious adverse events (AEs).

**Note:** Comparator group in the SWORD-1 & SWORD-2 trials: 52 weeks of ongoing ART followed by RPV/DTG (~48 weeks). f-u: Follow-up.
Figure 7: Meta-analysis of studies reporting data on drug-related adverse events (AEs).

f-u: Follow-up.

Note: Comparator group in the SWORD-1 & SWORD-2 trials: 52 weeks of ongoing ART followed by RPV/DTG (~48 weeks). Comparator group in the SPIRIT trial: 24 weeks of ongoing ART + 24 weeks of RPV/FTC/TDF.

Figure 8: Meta-analysis of studies reporting data on discontinuation due to adverse events (AEs).

f-u: Follow-up.

Note: Comparator group in the SWORD-1 & SWORD-2 trials: 52 weeks of ongoing ART followed by RPV/DTG (~48 weeks). Comparator group in the SPIRIT trial: 24 weeks of ongoing ART + 24 weeks of RPV/FTC/TDF.
in the comparator arms (from +12.4 to +29.0 mg/dL), while the STAAR study [7] failed to detect any differences in triglyceride changes from baseline between the RPV and comparator arms.

Six (2541 subjects) [9-11,14,34] and 3 studies (1865 subjects) [8,12] on cART-experienced virologically controlled subjects were included for weeks 48 and 96 (± 4 weeks), respectively. At week 48, all the lipids varied compared to their baseline levels, with a wide range among the studies. Specifically, LDL changes varied from -16.0 to +1.8 mg/dL in the RPV arms and from -14.0 to +8.52 mg/dL in the comparator arms. HDL changes spanned from -4.0 to +2.0 mg/dL in the RPV arms and from -4.0 to +5.16 mg/dL in the comparator arms, while total cholesterol changes ranged from -24.0 to +5.16 mg/dL in the comparator arms and from -4.0 to +0.39 mg/dL in the comparator arms. Triglyceride changes compared to baseline spanned from -64.0 to -4.0 mg/dL in the comparator arms (from +12.4 to +29.0 mg/dL), while the most recent data from ongoing trials were published in 2019 and involved cART-experienced virologically controlled subjects [8,33], while the most recent data from ongoing trials were published in 2019 and involved cART-experienced virologically controlled subjects [8]. In the ITT analysis of both the cART-naïve and experienced virologically controlled subjects, the virological response and the MD in the change in CD4 cell counts from baseline did not differ between the RPV and comparator arms, at either 48 or 96 weeks, with low variability among the studies. However, according to the baseline characteristics of naïve patients, compared to EFV, the difference in virological suppression favored RPV at both 48 and 96 weeks (+7% and +8%, respectively) among those starting cART with plasma HIV RNA < 100,000 cp/mL. Furthermore, among naïve patients starting cART with a CD4 count above 200 cells/μL, EFV reached a virological control rate similar to that of RPV only after 2 years of treatment. These results were also achieved in clinical practice in both naïve and cART-experienced patients with approximately 2 years of follow-up [15,16,19,21]. These results confirm previous evidence of RPV potency and efficacy in inhibiting a broad spectrum of HIV-1 genotypes and circulating recombinant forms, including K101E-, Y181C-, G190A- and K103N-mutated viruses, and in possessing generally lower half-maximal effective concentration values than those of other NNRTIs against specific HIV-1 isolates [43,44]. Notably, in 4 of the included studies, RPV was used in dual regimens (with dolutegravir, cabotegravir or darunavir/ritonavir) [8,9,11,28], and in 1 study, RPV doses were differentiated (either 25, 75 or 150 mg/day) [6,33]. In both cases, RPV potency in reaching viral undetectability was confirmed, as it was safe with no evidence of a dose-response relationship [33]. The safety profile of RPV was also similar to that of the comparator irrespective of the drug used (EFV, nevirapine or boosted protease inhibitors) in terms of both AEs and changes from baseline lipid levels. AEs leading to RPV discontinuation were relatively rare. In this analysis, pooling the naïve and experienced subjects could have introduced bias and increased the heterogeneity; the latter was also explained by the several different companions in RPV-anchored dual and three-drug regimens. In a previous meta-analysis, RPV showed lower rates of rashes and neurological AEs than EFV [30]; we have not performed subanalyses stratified according to the type of AEs; overall RPV has shown non-inferiority versus any control arm in the rate of drug-related AEs.

Among naïve patients at the longest follow-up, RPV was shown not to affect total and LDL cholesterol levels compared to the mild-to-moderate increase associated with the comparators and, despite its milder effect on a favorable increase in HDL cholesterol, the lowering effect on triglycerides in the RPV-anchored arm was in the opposite direction of the changes induced by the comparator drugs. Among cART-experienced virologically controlled subjects, RPV use in the first year from the switch was associated with a reduction in LDL and triglycerides (from a mild reduction to a mild increase in the comparator arms) and variable trends in HDL and total cholesterol (similarly to the comparators). At the longest follow-up, these differences were attenuated, with a significant persistence of lowered levels of total cholesterol. The results of this qualitative analysis of RCTs are in line with other studies that reported a neutral or favorable metabolic impact of RPV on lipids [45,46]. Interestingly, a recent phase IV RCT observed that patients switching from EFV to RPV (remaining on an FTC/TDF backbone) showed a decrease in the global amount of storage lipids and an increase in lysophosphatidylcholines and total steroids, resulting in an increment of metabolites with anti-inflammatory properties and a reduction in the repository of specific lipotoxic lipids [47]. Further studies are warranted to clarify the observed differential impact of RPV on lipid levels between cART-naive and cART-experienced
patients as well as the positive long-term consequences of its favorable metabolic impact on the several HIV-related comorbidities associated with alterations in lipid profiles, such as weight gain and HIV-associated neurocognitive disorders.

Limitations and Strengths

The main limitations of this meta-analysis are represented by: the variety of different comparators among the studies in cART-experienced patients; the patient data aggregation; the partially different time points for the efficacy/safety assessments; the limited data on lipid changes that did not allow us to perform a quantitative synthesis; the wide time-span of the included studies (2005-2019); the exclusion of non-English-language publications. Eight of the included RCTs were open-label, and thus, considered at an increased risk of performance bias. Nevertheless, since the assessed outcomes were objective measures, the risk of performance bias may still be restrained. Furthermore, our meta-analysis included only 4 studies using RPV-including dual regimens; only 1 out of the 8 studies assessing RPV-including regimens with tenofovir involved tenofovir alafenamide instead of disoproxil fumarate, and none reported data on long-acting injectable RPV. However, regarding the latter, two recent registartive studies conducted in naïve (after oral induction with dolutegravir and RPV) and in virologically controlled patients, observing no difference from the comparator arms. RPV proved to be also safe and well tolerated in both patient groups, with a similarly low rate of AEs and an advantageous impact on the lipid profile compared to the other treatment alternatives.

Acknowledgements

This work was supported by Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases; thanks to the collaboration of Mattia Trunfio (Research Fellow at the Unit of Infectious Diseases, Amedeo di Savoia Hospital, Department of Medical Science, University of Torino) in the drafting of the manuscript.

Author Contributions

All the Authors contributed equally to this work and participated in manuscript preparation and revision.

Competing Interests

Andrea Antinori (A.A.) has received honoraria for consultancies with Gilead Sciences, Viiv Healthcare, Merck Sharp & Dohme, Janssen-Cilag, Abbvie, and Bristol-Myers Squibb and has also received research grants from Gilead Sciences, Bristol-Myers Squibb, Janssen-Cilag, and Viiv Healthcare;

Adriano Lazzarin (A.L.) has received fees for advisory board participation and conference talks from BMS, Viiv, Gilead, MSD, Mylan, Abbvie, Janssen Cilag, and Teva;

Stefano Rusconi (S.R.) has received consulting fees and fee for advisory board participation from BMS, Gilead, MSD, Viiv, Janssen Cilag, Mylan;

Alessia Uglietti (A.U.), Daniela Mancusi (D.M.) and Roberta Termini (R.T.) are employees of Janssen-Cilag SpA, Italy;

Carlotta Galeone (C. G.) is consultant for Statinfo.

References

1. Ford N, Lee J, Andrieux-Meyer I, Calmy A (2011) Safety, efficacy, and pharmacokinetics of rilpivirine: Systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl) 3: 35-44.
2. Putcharoen O, Kerr SJ, Ruxrungtham K (2013) An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients. HIV AIDS (Auckl) 5: 231-241.
3. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, et al. (2011) Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 378: 238-246.
4. Cohen CJ, Andrade-Villanueva J, Ciotet B, Fourie J, Johnson MA, et al. (2011) Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected
with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet 378: 229-237.

5. Cohen CJ, Molina JM, Cassetti I, Chethotsaik P, Lazzarin A, et al. (2013) Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 27: 939-950.

6. Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santosoy M, et al. (2012) Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: Week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 28: 437-446.

7. Van Lunzen J, Antinori A, Cohen CJ, Arrabas JR, Wohl DA, et al. (2016) Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized phase 3b study. AIDS 30: 251-259.

8. Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, et al. (2019) Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV 6: e576-e587.

9. Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, et al. (2018) Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 391: 839-849.

10. Palella Jr FJ, Fisher M, Tebas P, Gazzard B, Ruane P, et al. (2014) Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 28: 335-344.

11. Maggiolo F, Filippo ED, Valenti D, Ortega PAS, Callegaro A (2016) NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe). J Acquir Immune Defic Syndr 72: 46-51.

12. Hagins D, Orkin C, Daar ES, Mills A, Brinson C, et al. (2018) Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med 19: 724-733.

13. Munderi P, Were E, Avihingsanon A, Mbida PAM, Mohapi L, et al. (2019) Switching at Low HIV-1 RNA into fixed dose combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV. South Afr J HIV Med 20: 949.

14. Petchkum P, Sungkanuparph S, Kiertiburanakul S, Phuphuakrat A (2019) Efficacy of Rilpivirine-based regimens as switch therapy from Nevirapine-based regimens in human immunodeficiency virus-infected patients with virological suppression: A Randomized Controlled Trial. Open Forum Infect Dis 6: 155.

15. Bagella P, De Socio GV, Ricci E, Menzaghi B, Martelli C, et al. (2018) Durability, safety, and efficacy of rilpivirine in clinical practice: Results from the SCOLTA project. Infect Drug Resist 11: 615-623.

16. Capetti AF, Sterrantino G, Cosso MV, Orofino GC, Barbarini G, et al. (2016) Switch to Dolutegravir plus Rilpivirine dual therapy in cART-experienced subjects: An Observational Cohort. PLoS One 11: e0164753.

17. Pasqua J, de Jesus SE, Arazo P, Crusells MJ, Rios MJ, et al. (2019) Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: A preliminary 24-week analysis (RIDAR study). BMC Infect Dis 19: 207.

18. Troya J, Ryan P, Ribera E, Podzamczer D, Hontaño V, et al. (2016) Abacavir/Lamivudine plus rilpivirine is an effective and safe strategy for hiv-1 suppressed patients: 48 Week results of the SIMRIKI retrospective study. PLoS One 11: e0164455.

19. Galizzi N, Galli L, Poli A, Gianotti N, Carini E, et al. (2018) Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. PLoS One 13: e0191300.

20. Gianotti N, Poli A, Nozza S, Spagnuolo V, Tambussi G, et al. (2015) Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. J Int AIDS Soc 18: 20037.

21. Sculier D, Gayet-Ageron A, Battegay M, Cavassinni M, Fehr J, et al. (2017) Rilpivirine use in the Swiss HIV cohort study: A prospective cohort study. BMC Infect Dis 17: 476.

22. Ministero della Salute (2019) Linee Guida Italiane sull’utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1.

23. EACS European AIDS Clinical Society (2019) EACS Guidelines version 10.0.

24. British HIV Association (2016) BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update).

25. British HIV Association (2019) BHIVA treatment guidelines: Interim statement on two-drug regimens.

26. Department of Health and Health Services (DHHS) (2019) Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.

27. Imaz A, Podzamczer D (2012) The role of rilpivirine in clinical practice: Strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy. AIDS Rev 14: 268-278.

28. Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, et al. (2015) Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): A randomised, phase 2b, dose-ranging trial. Lancet Infect Dis 15: 1145-1155.

29. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, et al. (2017) Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet 390: 1499-1510.

30. Li SL, Xu P, Zhang L, Sun GX, Lu ZJ (2014) Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1 infection (LATTE): A meta-analysis. HIV Clin Trials 15: 261-268.

31. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: e1000097.

32. Cohen C, Wohl D, Arribas JR, Henry K, Lunzen JV, et al. (2014) Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 28: 989-997.
33. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, et al. (2010) Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: Week 96 results of a phase Ib randomized trial. AIDS 24: 55-65.

34. DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, et al. (2017) Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: A randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV 4: e205-e213.

35. (2019) Speaker Abstracts. J Int AIDS Soc 22: e25263.

36. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, et al. (2012) Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 60: 33-42.

37. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366: 4898.

38. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.

39. Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9: 1-30.

40. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.

41. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.

42. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.

43. Wang Y, De Clercq E, Li G (2019) Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opin Drug Metab Toxicol 15: 813-829.

44. Viciana P (2017) Rilpivirine: The key for long-term success. AIDS Rev 19: 156-166.

45. Taramasso L, Tatarelli P, Ricci E, Maddeddu G, Menzaghi B, et al. (2018) Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). BMC Infect Dis 18: 357.

46. Di Biagio A, Riccardi N, Taramasso L, Capetti A, Cenderello G, et al. (2016) Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. Int J Antimicrob Agents 48: 551-554.

47. Curran A, Rull A, Navarro J, Vidal-González J, Martin-Castillo M, et al. (2020) Lipidomics reveals reduced inflammatory lipid species and storage lipids after switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. J Clin Med 9: 1246.

48. Orkin C, Arasteh K, Hernández-Mora MG, Pokrovsky V, Overton ET, et al. (2020) Long-acting Cabotegravir and Rilpivirine after oral induction for HIV-1 infection. N Engl J Med 382: 1124-1135.

49. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, et al. (2020) Long-acting Cabotegravir and Rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 382: 1112-1123.
### Supplementary Table 1: Change in CD4+ cell count in trials comparing rilpivirine-(RPV)-based regimens with other antiretroviral therapies (ART).

| Study                  | RPV group                                                                 | Comparator [p value*]                                                                 |
|------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| **Treatment-naïve patients** |                                                                           |                                                                                      |
| TMC278-C204            | 48-week (RPV 25 mg/day arm)                                               | 48-week (RPV 25 mg/day arm)                                                          |
| Pozniak 2010 [33]      | Change from BL (cells/µL), mean (SE), median 122.1 (11.8), 108             | Change from BL (cells/µL), mean (SE), median 126.5 (11.1), 120.5                      |
|                        | 96-week (RPV 25 mg/day arm)                                               | 96-week                                                                              |
|                        | Change from BL (cells/µL), mean (SE), median 145.8 (12.1), 138             | Change from BL (cells/µL), mean (SE), median 159.8 (13.4), 170.5                      |
| ECHO & THRIVE          | 48-week                                                                   | 48-week                                                                              |
| Cohen 2012 [36]        | Change from BL (cells/mm³), mean (95% CI) 192 (181-203)                    | Change from BL (cells/mm³), mean (95% CI) 176 (165-188)                               |
|                        | 96-week                                                                   | 96-week                                                                              |
|                        | Change from BL (cells/µL), mean (95% CI) 228 (215-240)                     | Change from BL (cells/µL), mean (95% CI) 219 (206-233)                                |
| STAR                   | 48-week                                                                   | 48-week                                                                              |
| Cohen 2014 [32] (week 48 results) | Change from BL (cells/µL), mean (SD) 200 (159)       | Change from BL (cells/µL), mean (SD) 191 (144)                                       |
| Van Lunzen 2016 [7] (week 96 results) | 96-week         | 96-week                                                                              |
|                        | Change from BL (cells/µL), mean (SD) 178 (189)         | Change from BL (cells/µL), mean (SD) 259 (191)                                       |
| **Treatment-experienced, virologically controlled patients** |                                                                           |                                                                                      |
| SPIRIT                 | 48-week                                                                   | 48 week                                                                               |
| Palella 2014 [10]      | Change from BL (cells/µL), mean 10                                        | Change from BL (~ 24 weeks BL ART & 24 weeks RPV + FTC + TDF) (cells/µL), mean -7   |
| LATTE                  | 48-week: 24-week induction (no RPV) + 24-week RPV                        | 24-week induction (no RPV) + 24-week RPV                                             |
| Margolis 2015 [28]     | Change from BL* (cells/µL), median (q1, q3) 219 (141, 343)                | Change from BL* (cells/µL), median (q1, q3) 216 (133.5, 363)                         |
|                        | 72-week: 24-week induction (no RPV) + 48-week RPV                        | 72-week: 24-week induction (no RPV) + 48-week RPV                                   |
|                        | Change from BL* (cells/µL), median (q1, q3) 205 (117, 339)                | Change from BL* (cells/µL), median (q1, q3) 208.5 (94, 355)                         |
|                        | 96-week: 24-week induction (no RPV) + 72-week RPV                        | 96-week: 24-week induction (no RPV) + 72-week RPV                                   |
|                        | Change from BL* (cells/µL), median (q1, q3) 259.5 (137, 355)              | Change from BL* (cells/µL), median (q1, q3) 289 (158, 415)                          |
| Probe                  | 48-week                                                                   | 48-week                                                                              |
| Maggiolo 2016 [11]     | Change from BL (cells/µL), mean (SD) 15 (184)                             | Change from BL (cells/µL), mean (SD) 16 (142)                                        |
| Study | RPV group | Comparator [p value*] |
|-------|-----------|----------------------|
| GS-US-366-1160 DeJesus 2017 [34] (week 48 results) Hagins 2018 [12] (week 96 results) | 48-week  
Change from BL (cells/µL), mean (SD)  
23 (156)  
96-week  
Change from BL (cells/µL), mean (SD)  
12 (199.8) | 48-week  
Change from BL (cells/µL), mean (SD)  
12 (153) [p = 0.31]  
96-week  
Change from BL (cells/µL), mean (SD)  
6 (153.2) [p = 0.64] |
| SWORD-1 & SWORD-2 Libre 2018 [9] (week 48 results) Aboud 2019 [8] (week 100 results) | 48-week  
Change from BL (cells/µL), median (q1, q3)  
28 (-55, 112.5)  
100-week  
Change from BL (cells/µL), median (q1, q3)  
33 (-51, 148) | 48-week  
Change from BL (cells/µL), median (q1, q3)  
22 (-46, 108)  
100-week  
Change from the late-switch BL (~ 48 week of RPV + DTG) (cells/µL), median (q1, q3)  
13 (-78, 98) |
| SALIF Munderi, et al. 2019 [13] | 48-week  
Change from BL (cells/mm³), mean (SD)  
26.2 (125.1) | 48-week  
Change from BL (cells/mm³), mean (SD)  
6.1 (140.1) |
| Petchkum 2019 [14] | 48-week  
BL - week 48 (cells/mm³), median (q1, q3)  
563 (457, 727) - 547 (417, 708) | 48-week  
BL - week 48 (cells/mm³), median (q1, q3)  
552 (434, 733) [p = 0.912] - 520 (424, 720) [p = 0.911] |

**Abbreviations:** BL: Baseline; DTG: Dolutegravir; RPV: Rilpivirine.

*for comparison with the RPV group, as reported in the publication.

°at study baseline, patients were treatment-naïve.
Supplementary Table 2: Changes in lipids in trials comparing rilpivirine (RPV)-based regimens with other antiretroviral therapies (ART).

| Study | RPV group | Comparator | p value* |
|-------|-----------|------------|----------|
| **Treatment naïve patients** | | | |
| TMC278-C204 Pozniak 2010 [33] | 96-week (RPV 25 mg/day arm) | 96-week | |
| | Change from BL (mg/dL), mean (SD) | Change from BL (mg/dL), mean (SD) | |
| | Total cholesterol: 10 (28) | Total cholesterol: 34 (31) | |
| | HDL cholesterol: 6 (10) | HDL cholesterol: 11 (12) | |
| | Total/HDL cholesterol: -0.4 (1.3) | Total/HDL cholesterol: -0.1 (0.9) | |
| | LDL cholesterol: 5 (25) | LDL cholesterol: 18 (28) | |
| | Triglycerides: -8 (75) | Triglycerides: 29 (87) | |
| ECHO & THRIVE Molina 2011 [3] (ECHO week 48 results) Cohen 2011 [4] (THRIVE week 48 results) Cohen 2013 [5] (ECHO & THRIVE week 96 results) | 48-week ECHO | 48-week ECHO | |
| | Change from BL (mmol/L), mean (95% CI) | Change from BL (mmol/L), mean (95% CI) | |
| | Total cholesterol: 0.03 (-0.06, 0.11) | Total cholesterol: 0.63 (0.53, 0.73) [p < 0.0001] | |
| | HDL cholesterol: 0.07 (0.04, 0.10) | HDL cholesterol: 0.24 (0.21, 0.27) [p < 0.0001] | |
| | Total/HDL cholesterol: -0.14 (-0.33, 0.05) | Total/HDL cholesterol: -0.24 (-0.40, -0.09) [p = 0.25] | |
| | LDL cholesterol: -0.04 (-0.10, 0.03) | LDL cholesterol: 0.31 (0.23-0.39) [p < 0.0001] | |
| | Triglycerides: -0.10 (-0.19, -0.01) | Triglycerides: 0.16 (-0.07, 0.38) [p = 0.01] | |
| | 48-week THRIVE | 48-week THRIVE | |
| | Change from BL (mmol/L), mean (95% CI) | Change from BL (mmol/L), mean (95% CI) | |
| | Total cholesterol: 0.08 (-0.01, 0.16) | Total cholesterol: 0.79 (0.69, 0.90) [p < 0.0001] | |
| | HDL cholesterol: 0.11 (0.08, 0.13) | HDL cholesterol: 0.27 (0.24, 0.30) [p < 0.0001] | |
| | Total/HDL cholesterol: -0.36 (-0.48, -0.25) | Total/HDL cholesterol: -0.28 (-0.38, -0.17) [p = 0.25] | |
| | LDL cholesterol: -0.02 (-0.09, 0.05) | LDL cholesterol: 0.44 (0.34, 0.53) [p < 0.0001] | |
| | Triglycerides: -0.07 (-0.17, 0.04) | Triglycerides: 0.14 (0.01, 0.26) [p < 0.0001] | |
| | 96-week ECHO & THRIVE | 96-week ECHO & THRIVE | |
| | Change from BL (mmol/L), mean (95% CI) | Change from BL (mmol/L), mean (95% CI) | |
| | Total cholesterol: 0.12 (0.06-0.18) | Total cholesterol: 0.74 (0.66-0.82) [p < 0.0001] | |
| | HDL cholesterol: 0.11 (0.09-0.13) | HDL cholesterol: 0.29 (0.26–0.31) [p < 0.0001] | |
| | Total/HDL cholesterol: NA | Total/HDL cholesterol: NA [p = 0.17] | |
| | LDL cholesterol: 0.03 (-0.02, 0.08) | LDL cholesterol: 0.37 (0.31-0.43) [p < 0.0001] | |
| | Triglycerides: -0.07 (-0.15, 0.005) | Triglycerides: 0.14 (0.04-0.25) [p < 0.0001] | |
| STAR Cohen 2014 [32] (week 48 results) Van Lunzen 2016 [7] (week 96 results) | 48-week | 48-week | |
| | Change from BL (mg/dL), mean | Change from BL (mg/dL), mean | |
| | Total cholesterol: 1 | Total cholesterol: 22 [p < 0.001] | |
| | HDL cholesterol: 2 | HDL cholesterol: 8 [p < 0.001] | |
| | Total/HDL cholesterol: -0.2 | Total/HDL cholesterol: -0.2 | |
| | LDL cholesterol: 1 | LDL cholesterol: 14 [p < 0.001] | |
| | Triglycerides: -8 | Triglycerides: 8 [p < 0.001] | |
| | 96-week | 96-week | |
| | Change from BL (mg/dL), mean (SD) | Change from BL (mg/dL), mean (SD) | |
| | Total cholesterol: 3 (33) | Total cholesterol: 25 (32) [p < 0.001] | |
| | HDL cholesterol: 2 (10) | HDL cholesterol: 9 (11) [p < 0.001] | |
| | Total/HDL cholesterol: -0.2 (1.1) | Total/HDL cholesterol: -0.2 (1.1) | |
| | LDL cholesterol: 2 (27) | LDL cholesterol: 15 (28) [p < 0.001] | |
| | Triglycerides: 8 (111) | Triglycerides: -5 (69) [p = 0.090] | |
| Study                     | RPV group            | Comparator [p value] |
|---------------------------|----------------------|---------------------|
| **Treatment-experienced, virologically controlled patients** |
| SPIRIT                    | 48-week              | 48-week             |
| Palella 2014 [10]         | Change from BL (mg/dl), mean | Change from the late switch BL (~24 weeks RPV + FTC + TDF) (mg/dl), mean |
|                           | Total cholesterol: -24 | Total cholesterol: -24 |
|                           | HDL cholesterol: -2   | HDL cholesterol: -4  |
|                           | Total/HDL cholesterol: -0.35 | Total/HDL cholesterol: -43 |
|                           | LDL cholesterol: -16  | LDL cholesterol: -14 |
|                           | Triglycerides: -64    | Triglycerides: -80   |
|                           | 24-week              | No data for the maintenance-exposed population |
|                           | Change from BL (~24 weeks of BL ART) (mg/dl), mean | No data for the maintenance-exposed population |
|                           | Total cholesterol: -1 | Total cholesterol: -1 |
|                           | HDL cholesterol: -1   | HDL cholesterol: -1  |
|                           | Total/HDL cholesterol: +0.08 | Total/HDL cholesterol: +0.08 |
|                           | LDL cholesterol: 0    | LDL cholesterol: 0   |
|                           | Triglycerides: +3     | Triglycerides: +3    |
| LATTE                     | No data for the maintenance-exposed population | No data for the maintenance-exposed population |
| Margolis 2015 [28]        |                      |                     |
| Probe                     | 48-week              | 48-week             |
| Maggiolo 2016 [11]        | BL - week 48 (mg/dL), mean (SD) | BL - week 48 (mg/dL), mean (SD) |
|                           | Total cholesterol: 183 (46) - 200 (40) | Total cholesterol: 184 (37) - 188 (44) |
|                           | HDL cholesterol: 47 (13) - 49 (17) | HDL cholesterol: 45 (12) - 45 (17) |
|                           | Total/HDL cholesterol: NA | Total/HDL cholesterol: NA |
|                           | LDL cholesterol: NA   | LDL cholesterol: NA  |
|                           | Triglycerides: 200 (181) - 173 (138) | Triglycerides: 128 (44) - 143 (63) |
| GS-US-366-1160            | 48-week              | 48-week             |
| DeJesus 2017 [34] (week 48 results) | Change from BL (mg/dL), median (q1, q3) | Change from BL (mg/dL), median (q1, q3) |
| Hagins 2018 [12] (week 96 results) | Total cholesterol: -9 (-27, 9) | Total cholesterol: -3 (-18, 13) [p < 0.0001] |
|                           | HDL cholesterol: -4 (-9, 2) | HDL cholesterol: -1 (-6, 4) [p = < 0.0001] |
|                           | Total/HDL cholesterol: 0.1 (-0.3, 0.5) | Total/HDL cholesterol: 0 (-0.3, 0.4) [p = 0.20] |
|                           | LDL cholesterol: -3 (-18, 13) | LDL cholesterol: -2 (-13, 11) [p = 0.20] |
|                           | Triglycerides: -4 (-35, 23) | Triglycerides: -2 (-27, 27) [p = 0.093] |
|                           | 96-week              | 96-week             |
|                           | Change from BL (mg/dL), median (q1, q3) | Change from BL (mg/dL) median (q1, q3) |
|                           | Total cholesterol: -13 (-32, 10) | Total cholesterol: -3 (-19, 15) [p < 0.001] |
|                           | HDL cholesterol: -4 (-11, 1) | HDL cholesterol: 0 (-6, 6) [p < 0.001] |
|                           | Total/HDL cholesterol: 0.1 (-0.4, 0.5) | Total/HDL cholesterol: 0 (-0.5, 0.4) [p = 0.06] |
|                           | LDL cholesterol: -2 (-20, 14) | LDL cholesterol: 0 (-13, 13) [p = 0.22] |
|                           | Triglycerides: 1 (-34, 24) | Triglycerides: 4 (-25, 35) [p = 0.14] |
| Study               | RPV group                                      | Comparator [p value*]                      |
|---------------------|------------------------------------------------|-------------------------------------------|
| SWORD-1 & SWORD-2   | 48-week                                       | 48-week                                   |
| Llibre 2018 [10]    | BL - week 48 (mg/dL), mean                    | BL - week 48 (mg/dL), mean               |
|                     | Total cholesterol: 184.3 - 186.1              | Total cholesterol: 186.7 - 187.0          |
|                     | HDL cholesterol: 52.3 - 54.1                  | HDL cholesterol: 53.3 - 54.7             |
|                     | Total/HDL cholesterol: 3.78 - 3.67            | Total/HDL cholesterol: 3.73 - 3.65       |
|                     | LDL cholesterol: 107.2 - 109.0                 | LDL cholesterol: 108.8 - 107.5           |
|                     | Triglycerides: 126.4 - 118.0                   | Triglycerides: 126.3 - 125.8             |
|                     | 100-week                                       | Change from BL (mg/dL), mean             |
|                     | Total cholesterol: 0.1                        | Total cholesterol: 0.06                  |
|                     | HDL cholesterol: 0.01                         | HDL cholesterol: -0.03                   |
|                     | Total/HDL cholesterol: 0.05                   | Total/HDL cholesterol: 0.11              |
|                     | LDL cholesterol: 0.15                         | LDL cholesterol: 0.16                    |
| SALIF               | No data                                       | No data                                   |
| Munderi 2019 [14]   | 48-week                                       | Change from BL (mg/dL), mean (95% CI)     |
|                     | Total cholesterol: -17.1 (-29.69, -4.4)        | Total cholesterol: 7.25 (-0.87, 15.38)    |
|                     | HDL cholesterol: -0.37 (-6.10, 5.36)          | HDL cholesterol: 5.16 (2.46, 7.86)       |
|                     | Total/HDL cholesterol: -0.31 (-0.75, 0.13)    | Total/HDL cholesterol: -0.22 (-0.47, 0.03)|
|                     | LDL cholesterol: 0.53 (-11.8, 12.86)          | LDL cholesterol: 8.52 (1.63, 15.41)       |
|                     | Triglycerides: -36.02 (-71.02, -1.12)         | Triglycerides: -12.25 (-40.93, 16.43)    |
| Petchkum2019 [16]   | 48-week                                       | Change from BL (mg/dL), mean (95% CI)     |
|                     | Total cholesterol: 7.25 (-0.87, 15.38)        | Total cholesterol: 7.25 (-0.87, 15.38)    |
|                     | HDL cholesterol: 5.16 (2.46, 7.86)            | HDL cholesterol: 5.16 (2.46, 7.86)       |
|                     | Total/HDL cholesterol: -0.22 (-0.47, 0.03)    | Total/HDL cholesterol: -0.22 (-0.47, 0.03)|
|                     | LDL cholesterol: 8.52 (1.63, 15.41)           | LDL cholesterol: 8.52 (1.63, 15.41)       |
|                     | Triglycerides: -12.25 (-40.93, 16.43)         | Triglycerides: -12.25 (-40.93, 16.43)    |

**Abbreviations:** BL: Baseline; DTG: Dolutegravir; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; NA: Not available; RPV: Rilpivirine.

* for comparison with the RPV group, as reported in the publication.

---

**Study**

| Study        | TMC278-C204 | ECHO+THRIVE | STAR | SPIRIT | LATTE | PROBE | GS-US-366-1160 | SWORD 1-2 | SALIF | Petchkum 2019 |
|--------------|-------------|-------------|------|--------|-------|-------|----------------|-----------|-------|--------------|
|              | +           | +           | +    | +      | +     | +     | +              | +         | +     | +            |

**Supplementary Figure 1:** Risk of bias according to the revised Cochrane risk-of-bias tool for randomized trials (RoB 2).
Supplementary Figure 2: Publication bias assessment (funnel plots, Egger and Begg and Mazumdar’s tests) for the plasma viral load outcome (panel A) and for the discontinuation due to adverse events outcome (panel B).

$p_{\text{Egger}} = 0.611; p_{\text{Begg and Mazumdar}} = 0.835.$
Supplementary Figure 3: Meta-analysis of studies reporting data on any adverse events (AEs).
f-u: Follow-up.

Note: Comparator group in the SWORD-1 & SWORD-2 trials: 52 weeks of ongoing ART followed by RPV/DTG (~48 weeks).